The Historical Evolution of Ocular Tuberculosis : Past, Present, and Future
Ocular involvement is a rare manifestation of tuberculosis. Four key issues historically faced by clinicians when diagnosing and treating ocular tuberculosis - diagnostic uncertainty, naturally heterogeneous presentations, limitations of existing laboratory diagnostic tools, and non-uniform treatment guidelines - continue to test today's physicians. Unparalleled scientific and clinical developments over the past century have greatly expanded the knowledge surrounding this challenging ophthalmic condition. Experience with large volumes of cases at tuberculosis-endemic centres has led to recent growth in knowledge and physician experience, perhaps more so in developing countries. Looking forward, the role of diverse new technologies, including artificial intelligence and proteomics, will advance ocular tuberculosis research. Efforts have been made to address the lack of standardized nomenclature, diagnostic uncertainty, and unvalidated, geographically variable treatment guidelines.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
---|---|
Enthalten in: |
Ocular immunology and inflammation - 30(2022), 3 vom: 03. Apr., Seite 593-599 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Betzler, Bjorn Kaijun [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antitubercular Agents |
---|
Anmerkungen: |
Date Completed 01.08.2022 Date Revised 22.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/09273948.2021.1992446 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332901920 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM332901920 | ||
003 | DE-627 | ||
005 | 20240222231855.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/09273948.2021.1992446 |2 doi | |
028 | 5 | 2 | |a pubmed24n1302.xml |
035 | |a (DE-627)NLM332901920 | ||
035 | |a (NLM)34752203 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Betzler, Bjorn Kaijun |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Historical Evolution of Ocular Tuberculosis |b Past, Present, and Future |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.08.2022 | ||
500 | |a Date Revised 22.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Ocular involvement is a rare manifestation of tuberculosis. Four key issues historically faced by clinicians when diagnosing and treating ocular tuberculosis - diagnostic uncertainty, naturally heterogeneous presentations, limitations of existing laboratory diagnostic tools, and non-uniform treatment guidelines - continue to test today's physicians. Unparalleled scientific and clinical developments over the past century have greatly expanded the knowledge surrounding this challenging ophthalmic condition. Experience with large volumes of cases at tuberculosis-endemic centres has led to recent growth in knowledge and physician experience, perhaps more so in developing countries. Looking forward, the role of diverse new technologies, including artificial intelligence and proteomics, will advance ocular tuberculosis research. Efforts have been made to address the lack of standardized nomenclature, diagnostic uncertainty, and unvalidated, geographically variable treatment guidelines | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a History | |
650 | 4 | |a artificial intelligence | |
650 | 4 | |a consumption | |
650 | 4 | |a inflammation | |
650 | 4 | |a ocular tuberculosis | |
650 | 4 | |a proteomics | |
650 | 4 | |a tuberculosis | |
650 | 4 | |a uveitis | |
650 | 7 | |a Antitubercular Agents |2 NLM | |
700 | 1 | |a Gunasekeran, Dinesh Visva |e verfasserin |4 aut | |
700 | 1 | |a Kempen, John |e verfasserin |4 aut | |
700 | 1 | |a Smith, Justine R |e verfasserin |4 aut | |
700 | 1 | |a McCluskey, Peter |e verfasserin |4 aut | |
700 | 1 | |a Nguyen, Quan Dong |e verfasserin |4 aut | |
700 | 1 | |a Pavesio, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Vishali |e verfasserin |4 aut | |
700 | 1 | |a Agrawal, Rupesh |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d 1993 |g 30(2022), 3 vom: 03. Apr., Seite 593-599 |w (DE-627)NLM091014069 |x 1744-5078 |7 nnns |
773 | 1 | 8 | |g volume:30 |g year:2022 |g number:3 |g day:03 |g month:04 |g pages:593-599 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2021.1992446 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 30 |j 2022 |e 3 |b 03 |c 04 |h 593-599 |